28277316|t|CXCL14 - CXCR4 and CXCL12 - CXCR4 Axes May Play Important Roles in the Unique Invasion Process of Endometrioid Carcinoma With MELF-Pattern Myoinvasion
28277316|a|The term " MELF-pattern myometrial invasion " (MELF pattern) denotes an unusual morphology of myometrial invasion in endometrioid carcinomas, and is associated with frequent lymphovascular invasion and lymph node metastasis. In this study, tumor cells were directly collected from a MELF pattern site, using laser microdissection. Comprehensive microarray analysis of the genes was conducted, and based on the results, expression of a metastasis progression gene, CXCR4, and its ligands CXCL14 and CXCL12, was further investigated. In vitro studies of endometrioid carcinoma cell lines revealed elevated invasion activity in a manner dependent on the CXCL14 - CXCR4 or CXCL12 - CXCR4 axis. Immunohistochemical analysis of 93 (MELF group, 46; non-MELF group, 47) cases illustrated CXCR4 was expressed in all endometrioid carcinomas, while based on CXCL14 and CXCL12 expression score, high proportions of cells were positive at the sites of the MELF pattern (P<0.01). There was no significant difference in progression-free survival or overall survival between MELF group and non-MELF group by Kaplan-Meier analysis. These findings suggest a possibility that cells at the sites of MELF pattern had acquired increased invasiveness through the function of the CXCL14 - CXCR4 and CXCL12 - CXCR4 axes.
28277316	0	6	CXCL14	T116,T129	C1335988
28277316	9	14	CXCR4	T116,T192	C2352110
28277316	19	25	CXCL12	T116,T129	C1528383
28277316	28	33	CXCR4	T116,T192	C2352110
28277316	78	86	Invasion	T033	C1269955
28277316	87	94	Process	T067	C1522240
28277316	98	120	Endometrioid Carcinoma	T191	C0206687
28277316	126	138	MELF-Pattern	T082	C0449774
28277316	139	150	Myoinvasion	T033	C1269955
28277316	162	174	MELF-pattern	T082	C0449774
28277316	175	185	myometrial	T029	C0521387
28277316	186	194	invasion	T033	C1269955
28277316	198	210	MELF pattern	T082	C0449774
28277316	223	230	unusual	T080	C2700116
28277316	231	241	morphology	T080	C0332437
28277316	245	255	myometrial	T029	C0521387
28277316	256	264	invasion	T033	C1269955
28277316	268	291	endometrioid carcinomas	T191	C0206687
28277316	300	315	associated with	T080	C0332281
28277316	325	348	lymphovascular invasion	T033	C1708790
28277316	353	374	lymph node metastasis	T191	C0024232
28277316	391	402	tumor cells	T025	C0334227
28277316	417	426	collected	T078	C1516695
28277316	434	446	MELF pattern	T082	C0449774
28277316	459	480	laser microdissection	T059	C1113652
28277316	482	495	Comprehensive	T080	C1880156
28277316	496	515	microarray analysis	T059	C1449575
28277316	523	528	genes	T028	C0017337
28277316	570	580	expression	T045	C1171362
28277316	586	620	metastasis progression gene, CXCR4	T116,T192	C2352110
28277316	630	637	ligands	T044	C1749457
28277316	638	644	CXCL14	T116,T129	C1335988
28277316	649	655	CXCL12	T116,T129	C1528383
28277316	669	681	investigated	T169	C1292732
28277316	683	699	In vitro studies	T062	C0681828
28277316	703	725	endometrioid carcinoma	T191	C0206687
28277316	726	736	cell lines	T025	C0085983
28277316	746	754	elevated	T080	C3163633
28277316	755	763	invasion	T033	C1269955
28277316	764	772	activity	T052	C0441655
28277316	802	808	CXCL14	T116,T129	C1335988
28277316	811	816	CXCR4	T116,T192	C2352110
28277316	820	826	CXCL12	T116,T129	C1528383
28277316	829	834	CXCR4	T116,T192	C2352110
28277316	841	869	Immunohistochemical analysis	T059	C1441616
28277316	877	887	MELF group	T078	C0441833
28277316	893	907	non-MELF group	T078	C0441833
28277316	931	936	CXCR4	T116,T192	C2352110
28277316	941	950	expressed	T045	C1171362
28277316	958	981	endometrioid carcinomas	T191	C0206687
28277316	998	1004	CXCL14	T116,T129	C1335988
28277316	1009	1015	CXCL12	T116,T129	C1528383
28277316	1016	1026	expression	T045	C1171362
28277316	1027	1032	score	T081	C0449820
28277316	1034	1050	high proportions	T081	C1709707
28277316	1054	1059	cells	T025	C0007634
28277316	1065	1073	positive	T033	C1446409
28277316	1081	1086	sites	T082	C0205145
28277316	1094	1106	MELF pattern	T082	C0449774
28277316	1127	1152	no significant difference	T033	C0243095
28277316	1156	1181	progression-free survival	T081	C0242792
28277316	1185	1201	overall survival	T081	C4086681
28277316	1210	1220	MELF group	T078	C0441833
28277316	1225	1239	non-MELF group	T078	C0441833
28277316	1243	1264	Kaplan-Meier analysis	T081	C1720943
28277316	1308	1313	cells	T025	C0007634
28277316	1321	1326	sites	T082	C0205145
28277316	1330	1342	MELF pattern	T082	C0449774
28277316	1356	1365	increased	T081	C0205217
28277316	1366	1378	invasiveness	T046	C0027626
28277316	1391	1399	function	T039	C0031843
28277316	1407	1413	CXCL14	T116,T129	C1335988
28277316	1416	1421	CXCR4	T116,T192	C2352110
28277316	1426	1432	CXCL12	T116,T129	C1528383
28277316	1435	1440	CXCR4	T116,T192	C2352110